The Japan epigenetics market held a market value of USD 22.4 million in 2020 and is estimated to reach USD 48.6 million by the year 2027. The market is anticipated to register a CAGR of 12.8% during the forecast period.
Epigenetics is the study of how the behaviors and environment can cause variations that impact the way the person’s genes work. In contrast to genetic changes, epigenetic changes are reversible and do not change the DNA sequence of the person, but the process can change how the body reads a DNA sequence.
The rising research initiatives taken by prominent players in the epigenetics market in Japan is projected to drive the growth rate of the market. The prominent pharmaceutical companies are in favour of investing in the epigenetics area in the promising country of Japan. The rising applications of epigenetics in oncology area also boosts the market growth.
On the other hand, high costs of epigenetics instruments make it affordable for research labs in developing economies to invest in this equipment. Furthermore, the lack of skilled workforce in developing and underdeveloped countries is hampering the growth of the market.
Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry
The prominent players in the market are focused on investing in research to develop innovative products and cater to services of end users and other stakeholders. For instance, in April 2021, Merck, a leading science and technology company, announced an investment of EUR 20 million to expand research and development and manufacturing capabilities at its site in Shizuoka, Japan. The investment is scheduled to be completed by January 2022. Thus, such steps drive the growth rate of the market.
Rising adoption of epigenetics for cancer treatment
Epigenetic dysregulation is generally related to human disease, especially cancer. With the growth of several drugs pointing at epigenetic regulators, epigenetic targeted mechanisms have been applied in the treatment of hematological distortions and has unveiled feasible therapeutic potential for cancers. Epigenetics therapy has been proven to be a successful method for the treatment of diverse malignancies. The rise in awareness and adoption of these mechanisms is fueling the growth of the market for epigenetics in Japan.
The Japan epigenetics market is segmented into product type, technology, application, and end user.
The kits segment held the largest market share in 2020 with a market share of around 22%. This maximum share owes to the high usage of kits in epigenetics mechanisms. The ChIP kits segment is growing substantially and the market size is projected to hit USD 5 million by 2027. The services segment size will hit USD 6 million by 2025.
The DNA methylation segment held the largest share owing to the high usage of this technique in the research and academic institutes. Moreover, bromodomains segment is projected to be the fastest growing segment with a CAGR of 14%.
The oncology segment is anticipated to grow at the largest share of about 55% owing to the rising applications of epigenetic in cancer treatment. The rising prevalence of cancer in Japan contributes heavily to the growth rate of this segment. Based on non-oncology, the autoimmune sub-segment is anticipated to grow at a rate of 13.2%.
The pharmaceutical & biotechnology companies segment held the largest share owing to the tremendous usage of epigenetic mechanisms by these firms. The contract research organizations segment is expected to grow at the fastest growth rate of 13% over the forecast period.
Key players operating in the Japan epigenetics market include Epigeneron, National Institute of Genetics, Rhelixa Inc, Riken, Illumina, Inc., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Co., Abcam PLC, among others.
The prominent five players in the market hold approximately 50% of the market share. These market players are involved in strategic initiatives, such as collaborations, mergers & acquisitions, product launch, and expansions to sustain in the market. For instance, in January 2020, Illumina received product approval certification for the MiSeqDx instrument with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This registration permits for the distribution of the MiSeqDx as a Class I medical device in Japan and establishes Illumina K.K. as the marketing authorization holder.
The rising research initiatives taken by prominent players in the epigenetics market in Japan is projected to drive the growth rate of the market. The prominent pharmaceutical companies are in favour of investing in the epigenetics area in the promising country of Japan. The rising applications of epigenetics in oncology area also boosts the market growth.
On the other hand, high costs of epigenetics instruments make it affordable for research labs in developing economies to invest in this equipment. Furthermore, the lack of skilled workforce in developing and underdeveloped countries is hampering the growth of the market.
Growth Influencers:
Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry
The prominent players in the market are focused on investing in research to develop innovative products and cater to services of end users and other stakeholders. For instance, in April 2021, Merck, a leading science and technology company, announced an investment of EUR 20 million to expand research and development and manufacturing capabilities at its site in Shizuoka, Japan. The investment is scheduled to be completed by January 2022. Thus, such steps drive the growth rate of the market.
Rising adoption of epigenetics for cancer treatment
Epigenetic dysregulation is generally related to human disease, especially cancer. With the growth of several drugs pointing at epigenetic regulators, epigenetic targeted mechanisms have been applied in the treatment of hematological distortions and has unveiled feasible therapeutic potential for cancers. Epigenetics therapy has been proven to be a successful method for the treatment of diverse malignancies. The rise in awareness and adoption of these mechanisms is fueling the growth of the market for epigenetics in Japan.
Segments Overview:
The Japan epigenetics market is segmented into product type, technology, application, and end user.
By Product Type
- Reagents
- Kits
- Bisulfite Conversion Kits
- ChIP Kits
- RNA Kit
- Others
- Instruments
- Software Tools
- EpiGRAPH
- BiQ Analyzer
- RnBeads
- Others
- Enzymes
- Proteins & Peptides
- Antibodies
- Services
The kits segment held the largest market share in 2020 with a market share of around 22%. This maximum share owes to the high usage of kits in epigenetics mechanisms. The ChIP kits segment is growing substantially and the market size is projected to hit USD 5 million by 2027. The services segment size will hit USD 6 million by 2025.
By Technology
- DNA Methylation (Largest Market Share)
- Histone Methylation
- Histone Acetylation
- Bromodomains (Fastest Growing segment; CAGR: 14%)
- Non-coding RNA
- Others
The DNA methylation segment held the largest share owing to the high usage of this technique in the research and academic institutes. Moreover, bromodomains segment is projected to be the fastest growing segment with a CAGR of 14%.
By Application
- Oncology
- Non-oncology
- Cardiovascular diseases
- Neurodegenerative
- Autoimmune
The oncology segment is anticipated to grow at the largest share of about 55% owing to the rising applications of epigenetic in cancer treatment. The rising prevalence of cancer in Japan contributes heavily to the growth rate of this segment. Based on non-oncology, the autoimmune sub-segment is anticipated to grow at a rate of 13.2%.
By End Users
- Academic and Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Research and Consulting Firms
The pharmaceutical & biotechnology companies segment held the largest share owing to the tremendous usage of epigenetic mechanisms by these firms. The contract research organizations segment is expected to grow at the fastest growth rate of 13% over the forecast period.
Competitive Landscape
Key players operating in the Japan epigenetics market include Epigeneron, National Institute of Genetics, Rhelixa Inc, Riken, Illumina, Inc., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Co., Abcam PLC, among others.
The prominent five players in the market hold approximately 50% of the market share. These market players are involved in strategic initiatives, such as collaborations, mergers & acquisitions, product launch, and expansions to sustain in the market. For instance, in January 2020, Illumina received product approval certification for the MiSeqDx instrument with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This registration permits for the distribution of the MiSeqDx as a Class I medical device in Japan and establishes Illumina K.K. as the marketing authorization holder.
The Japan epigenetics market report provides insights on the below pointers:
- Market Penetration: Provides comprehensive information on the market offered by the prominent players
- Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
- Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the Japan epigenetics market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
- Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
- Pricing Analysis: Pricing analysis of various metals and other components used in the manufacturing of epigenetic tools
- Manufacturing Cost Analysis: Cost-share of various components in epigenetics market, cost analysis of kits, Cost Analysis of reagents, Unit Cost Analysis of instruments, Cell Component Cost Analysis - software tools
The Japan epigenetics market report answers questions such as:
- What is the market size and forecast of the Japan epigenetics market?
- What are the inhibiting factors and impact of COVID-19 on the Japan epigenetics market during the assessment period?
- Which are the products/segments/applications/areas to invest in over the assessment period in the Japan epigenetics market?
- What is the competitive strategic window for opportunities in the Japan epigenetics market?
- What are the technology trends and regulatory frameworks in the Japan epigenetics market?
- What is the market share of the leading players in the Japan epigenetics market?
- What modes and strategic moves are considered favorable for entering the Japan epigenetics market?
Table of Contents
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 4. Japan Epigenetics Market Overview
Chapter 5. Japan Epigenetics Market, By Product Type
Chapter 6. Japan Epigenetics Market, By Technology
Chapter 7. Japan Epigenetics Market, By Application
Chapter 8. Japan Epigenetics Market, By End Users
Chapter 9. Company Profile (Company Overview, Financial Matrix, Sales Composition Ration, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Epigeneron
- National Institute of Genetics
- Rhelixa Inc
- Riken
- Illumina, Inc.
- Daiichi Sankyo Company, Limited
- Takeda Pharmaceutical Co.
- Abcam PLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 92 |
| Published | October 2021 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD | $ 22.4 million |
| Forecasted Market Value ( USD | $ 48.6 million |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | Japan |
